Innate Pharma SA (IPHYF) AI Stock Analysis

Company Guidance

Innate is targeting the first patient in TELLOMAK-3 in Q1 2027, with a filing for accelerated approval in Sezary Syndrome currently planned for the second half of 2027; the company expects lacutamab to be listed in the NCCN guidelines for both Sezary Syndrome and mycosis fungoides and expects some off label usage in the first line setting. PACIFIC-9 enrollment is complete, with the Phase 3 readout expected in the second half of 2026, and IPH4.5 thousand initial Phase 1 dose escalation data are scheduled for November 18, 2026; the company expects relevant and informative safety data and response data from 11 different indications and 76 patients. The $75 million Sobi upfront payment and €30 million equity offering, representing €28 million in expected net proceeds, are expected to extend cash runway through the end of the first quarter of 2028, and the company is funded to take IPH4.5 thousand forward seamlessly into dose optimization, while broadening the program across additional tumor types would require additional funding. Pricing research established that lacutamab can be priced between $500 thousand and $650 thousand per patient per annum, and the monalizumab agreement includes up to $825 million in additional potential milestones, double digit royalties outside Europe, and 50% profit sharing in Europe.